Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas

World Journal of Surgery
Melanie L RichardsThomas J Giordano

Abstract

Enterochromaffin-like (ECL) tumors are documented in patients with hypergastrinemia secondary to chronic atrophic gastritis or with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1 (ZES-MEN-1). In patients with ECL tumors and atrophic gastritis, normogastrinemia after antrectomy has resulted in resolution, regression, or stabilization of ECL tumors. The natural history of ECL tumors associated with ZES-MEN-1 following normalization of gastrin levels after gastrinoma resection has not been previously reported. The purpose of this study was to determine the course of ECL tumors in patients with ZES-MEN-1 following normalization of serum gastrin levels after gastrinoma resection. Two patients with ZES-MEN-1 had biopsy-proven ECL tumors on endoscopic evaluation. They then underwent surgical exploration that included distal pancreatectomy, enucleation of pancreatic head tumors, duodenotomy with excision of submucosal tumors, and peripancreatic lymphadenectomy. Gastric ECL tumors larger than 1.0 cm were locally excised. Patients underwent long-term follow-up with biochemical and endoscopic surveillance. Normogastrinemia was achieved and sustained following gastrinoma resection in two patients with ZES-MEN-1. Periodi...Continue Reading

Citations

Sep 15, 2012·Current Gastroenterology Reports·Mark Kidd, Bjorn I Gustafsson
Sep 12, 2009·Journal of Gastroenterology and Hepatology·Andrew D HopperMichael P Swan
Nov 5, 2011·Gut·John K RamageUNKNOWN UK and Ireland Neuroendocrine Tumour Society
Jun 22, 2011·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·M B Niederle, B Niederle
May 4, 2013·Gastroenterology Clinics of North America·Mark KiddIrvin M Modlin
Aug 3, 2006·Surgical Oncology Clinics of North America·Rebecca S Sippel, Herbert Chen
Oct 25, 2006·Alimentary Pharmacology & Therapeutics·M D Burkitt, D M Pritchard
Aug 23, 2005·Cancer Chemotherapy and Biological Response Modifiers·Dan Granberg, Kjell Oberg
Oct 29, 2005·Best Practice & Research. Clinical Gastroenterology·Gianfranco Delle FaveFrancesco Panzuto
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Göran Akerström, Per Hellman
May 31, 2012·Endocrine-related Cancer·Andrea FrillingIrvin Mark Modlin
Dec 1, 2007·European Journal of Gastroenterology & Hepatology·Sylvain ManfrediJean-François Bretagne
Dec 23, 2006·American Journal of Physiology. Gastrointestinal and Liver Physiology·Tonje S SteigedalAstrid Laegreid
Jan 11, 2020·The Journal of Clinical Endocrinology and Metabolism·Ryan EndallJohn Burgess
Jan 23, 2020·International Journal of Molecular Sciences·Denis M McCarthy
Nov 28, 2008·Scandinavian Journal of Gastroenterology·Karin BakkelundHelge L Waldum
Jan 29, 2021·Clinical Endocrinology·Jerena ManoharanDetlef K Bartsch
Apr 12, 2021·Annales d'endocrinologie·Aurore GeslotDelphine Vezzosi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.